These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 17565587

  • 41. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication.
    Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K.
    Arch Virol; 2010 Apr; 155(4):601-5. PubMed ID: 20204428
    [Abstract] [Full Text] [Related]

  • 42. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system.
    Larkin J, Jin L, Farmen M, Venable D, Huang Y, Tan SL, Glass JI.
    J Interferon Cytokine Res; 2003 May; 23(5):247-57. PubMed ID: 12804067
    [Abstract] [Full Text] [Related]

  • 43. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.
    Nishimura G, Ikeda M, Mori K, Nakazawa T, Ariumi Y, Dansako H, Kato N.
    Antiviral Res; 2009 Apr; 82(1):42-50. PubMed ID: 19428594
    [Abstract] [Full Text] [Related]

  • 44. Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems.
    Cagnon L, Wagaman P, Bartenschlager R, Pietschmann T, Gao T, Kneteman NM, Tyrrell DL, Bahl C, Niven P, Lee S, Simmen KA.
    J Virol Methods; 2004 Jun 01; 118(1):23-31. PubMed ID: 15158065
    [Abstract] [Full Text] [Related]

  • 45. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A.
    Antiviral Res; 2007 Jan 01; 73(1):78-83. PubMed ID: 16945431
    [Abstract] [Full Text] [Related]

  • 46. Effect of alpha interferon on the hepatitis C virus replicon.
    Guo JT, Bichko VV, Seeger C.
    J Virol; 2001 Sep 01; 75(18):8516-23. PubMed ID: 11507197
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway.
    Luquin E, Larrea E, Civeira MP, Prieto J, Aldabe R.
    Antiviral Res; 2007 Nov 01; 76(2):194-7. PubMed ID: 17675168
    [Abstract] [Full Text] [Related]

  • 52. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
    Escuret V, Martin A, Durantel D, Parent R, Hantz O, Trépo C, Menguy T, Bottius E, Dardy J, Maral J, Escary JL, Zoulim F.
    Antimicrob Agents Chemother; 2006 Dec 01; 50(12):3984-91. PubMed ID: 17030563
    [Abstract] [Full Text] [Related]

  • 53. Screening for hepatitis C virus antiviral activity with a cell-based secreted alkaline phosphatase reporter replicon system.
    Bourne N, Pyles RB, Yi M, Veselenak RL, Davis MM, Lemon SM.
    Antiviral Res; 2005 Aug 01; 67(2):76-82. PubMed ID: 15927278
    [Abstract] [Full Text] [Related]

  • 54. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L, Bigger C.
    J Virol; 2003 Jan 01; 77(2):1092-104. PubMed ID: 12502825
    [Abstract] [Full Text] [Related]

  • 55. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
    Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, Orito E, Ohno T, Sugihara K, Hasegawa I, Fujiwara K, Ito K, Ozasa A, Mizokami M, Wakita T.
    J Clin Microbiol; 2005 Nov 01; 43(11):5679-84. PubMed ID: 16272504
    [Abstract] [Full Text] [Related]

  • 56. Novel robust hepatitis C virus mouse efficacy model.
    Zhu Q, Oei Y, Mendel DB, Garrett EN, Patawaran MB, Hollenbach PW, Aukerman SL, Weiner AJ.
    Antimicrob Agents Chemother; 2006 Oct 01; 50(10):3260-8. PubMed ID: 17005803
    [Abstract] [Full Text] [Related]

  • 57. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J.
    Hepatology; 2006 Apr 01; 43(4):761-70. PubMed ID: 16557546
    [Abstract] [Full Text] [Related]

  • 58. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K.
    Biochem Biophys Res Commun; 2006 May 12; 343(3):879-84. PubMed ID: 16564500
    [Abstract] [Full Text] [Related]

  • 59. Inhibition of hepatitis C virus replication by arsenic trioxide.
    Hwang DR, Tsai YC, Lee JC, Huang KK, Lin RK, Ho CH, Chiou JM, Lin YT, Hsu JT, Yeh CT.
    Antimicrob Agents Chemother; 2004 Aug 12; 48(8):2876-82. PubMed ID: 15273095
    [Abstract] [Full Text] [Related]

  • 60. [Influence of miR-122 on IFN-α treatment for HCV infection].
    Li SJ, Chen Z, Zhu HH.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Nov 12; 40(6):588-92, 652. PubMed ID: 22190517
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.